Company: Aevumed, Inc.
Patent Number: 12697114
Title: Scaffold and suture anchoring device
Soft tissue tears are a common orthopedic injury, and traditional repair methods that rely solely on mechanical fasteners often fail to provide adequate healing because they introduce new weak points into already compromised tissue. Aevumed, Inc. has developed an innovative solution to this problem with their newly patented tool, which combines a unique grasper mechanism with retractable needles. This design allows surgeons to simultaneously deliver and anchor a biological or synthetic healing scaffold directly to the damaged tissue using sutures, effectively supporting the repair site both mechanically and biologically without causing further harm.
Award Winning Innovation in Pennsylvania
This exceptional advancement in medical device engineering is the reason the invention won the Patent of the Month for the Pennsylvania state for the month of September 2026, granted by Swanson Reed. Aevumed, Inc., based in Malvern, Pennsylvania, successfully engineered a practical, minimally invasive surgical instrument that directly addresses a major gap in orthopedic care. Swanson Reed recognized this patent not only for its technical ingenuity but also for its potential to significantly improve postoperative patient outcomes and reduce recovery times, representing a prime example of the high caliber life sciences innovation occurring within the state.
US R&D Tax Credit Eligibility
The practical applications of developing this scaffold and suture anchoring device align perfectly with the requirements for the United States Research and Development (R&D) tax credit. To bring this invention from concept to reality, engineers would need to conduct extensive prototyping and testing to resolve technical uncertainties regarding the deployment mechanism, the interaction between the retractable needles and various scaffold materials, and the overall ergonomics of the tool. The iterative design process, material science evaluations, and clinical validation efforts required to ensure the device functions safely and effectively are qualified research activities. By leveraging the R&D tax credit, companies in the medical device sector can recoup a portion of these development costs, enabling them to reinvest in further technological and medical breakthroughs.
